Your session is about to expire
← Back to Search
Ipatasertib for Breast Cancer (IPATunity130 Trial)
IPATunity130 Trial Summary
This trial will compare the effectiveness of a new drug combination versus a placebo for people with aggressive breast cancer that has spread.
- Breast Cancer
IPATunity130 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowIPATunity130 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.IPATunity130 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
For what purpose is Paclitaxel most often prescribed?
"Neoplasm metastasis is most commonly treated with Paclitaxel. Paclitaxel is also effective at treating other conditions such as kaposi sarcoma, fallopian tubes cancer, and ovarian cancer."
Could you please explain the dangers associated with Paclitaxel?
"Paclitaxel has been given a score of 3 for safety by our team at Power. This is because Phase 3 trials, of which this is one, provide some evidence of efficacy as well as multiple rounds of data supporting safety."
Could you please tell me what other scientific research has been conducted with Paclitaxel?
"At this moment, 899 different clinical trials for Paclitaxel are ongoing with 236 of them being in Phase 3. Most of the research for Paclitaxel is being conducted in Adelaide, South Australia; however, there are 47776 total locations running clinical trials for Paclitaxel."
Share this study with friends
Copy Link
Messenger